Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

This study has been completed.

First Received: September 8, 2005 Last Updated: March 14, 2007 History of Changes

Sponsored by:	Wyeth
Information provided by:	Wyeth
ClinicalTrials.gov Identifier:	NCT00161668

Purpose

This study is designed to assess the safety of Mylotarg therapy in routine practice.

Condition	Intervention	Phase
Acute Myeloid Leukemia	Drug: Mylotarg	Phase IV

MedlinePlus related topics: Leukemia, Adult Acute Leukemia, Adult Chronic

Drug Information available for: Gemtuzumab ozogamicin

Study Type:	Observational
Study Design:	Natural History, Longitudinal, Defined Population, Prospective Study
Official Title:	Prospective Observational Study of Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

Further study details as provided by Wyeth:

Estimated Enrollment:	500
Study Start Date:	October 2001

Eligibility

Criteria

Inclusion Criteria: - Treated by Mylotarg - Provide ICF

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00161668

Sponsors and Collaborators

Wyeth

Investigators

Study Director:

Medical Monitor

Wyeth

More Information

No publications provided

Study ID Numbers:	0903X-100847
Study First Received:	September 8, 2005
Last Updated:	March 14, 2007
ClinicalTrials.gov Identifier:	NCT00161668 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by Wyeth:

Leukemia

Study placed in the following topic categories:

Leukemia
Acute Myelocytic Leukemia
Leukemia, Myeloid
Gemtuzumab
Leukemia, Myeloid, Acute

Additional relevant MeSH terms:

Leukemia
Neoplasms
Neoplasms by Histologic Type
Antineoplastic Agents
Therapeutic Uses

Leukemia, Myeloid
Gemtuzumab
Leukemia, Myeloid, Acute
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 07, 2009